A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects

A Phase I Study to Evaluate the Relative Bioavailability of Different HRS-1893 Formulations and the Effect of Food on the Pharmacokinetics of HRS-1893 Tablets in Healthy Subjects

This Phase I clinical trial will investigate the relative bioavailability between two formulations of HRS-1893 tablets and the influence of food on the drug's pharmacokinetics in healthy adult participants. The safety and tolerability of HRS-1893 will also be monitored.

Study Overview

• Status: Completed
• Conditions: Cardiomyopathy
• Intervention / Treatment: Drug: HRS-1893 tablet A; Drug: HRS-1893 tablet B

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Beijing Municipality
    • Beijing, Beijing Municipality, China, 100029
      • Beijing Anzhen Hospital, Capital Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Subjects aged 18 to 55 years (inclusive), regardless of gender.
2. Body mass index (BMI) between 19 and 28 kg/m² (inclusive), with body weight ≥50.0 kg and <90.0 kg for men, and ≥45.0 kg and <90.0 kg for women.
3. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment.
4. No clinically significant abnormalities on the 12-lead ECG.
5. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.

Exclusion Criteria:

1. Subjects with suspected hypersensitivity to the investigational drug or any excipient.
2. The subject has a history of syncope.
3. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) >140 mmHg or <90 mmHg; OR Diastolic Blood Pressure (DBP) >90 mmHg or <60 mmHg, as determined by the investigator to be clinically significant.
4. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption.
5. A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody/antigen (HIV-Ab/Ag).
6. Subjects who meet any of the following criteria will be excluded: (1) Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening. (2) Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits). (3) Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration. (4) Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse.
7. History of substance abuse.
8. Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded.
9. Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HRS-1893 tablet A and HRS-1893 tablet B Group	Drug: HRS-1893 tablet A; Specified dose on specified days.; Drug: HRS-1893 tablet B; Specified dose on specified days.
Experimental: HRS-1893 tablet B Group	Drug: HRS-1893 tablet B; Specified dose on specified days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Peak concentration (Cmax)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
Area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC0-t)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.

Secondary Outcome Measures

Outcome Measure	Time Frame
Time to reach peak concentration (Tmax)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
Elimination half-life (t1/2)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
Apparent clearance (CL/F)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
Apparent volume of distribution (Vz/F)	From Day 1 to Day 25 in part 1, from Day 1 to Day 17 in part 2.
The incidence and severity of any adverse events (AEs)	From Day 1 to Day 29 in part 1, from Day 1 to Day 21 in part 2.

Collaborators and Investigators

• Sponsor: Shandong Suncadia Medicine Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 11, 2025
• Primary Completion (Actual): March 21, 2026
• Study Completion (Actual): March 21, 2026

Study Registration Dates

• First Submitted: November 26, 2025
• First Submitted That Met QC Criteria: December 7, 2025
• First Posted (Actual): December 9, 2025

Study Record Updates

• Last Update Posted (Actual): April 2, 2026
• Last Update Submitted That Met QC Criteria: April 1, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Heart Diseases; Cardiomyopathies
• Other Study ID Numbers: HRS-1893-106

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No